Impaired cardiac function or clinically significant cardiac disease including any of the following:\r\n* Congenital long QT syndrome\r\n* Screening electrocardiogram (ECG) with corrected QT (QTc) interval >=  milliseconds\r\n* Myocardial infarction (MI) or unstable angina =<  months of course , day  (CD); however, subjects with a history of MI between  and  months who are asymptomatic and have had a negative cardiac risk assessment (treadmill stress test, nuclear medicine stress test, or stress echocardiogram) since the event would be eligible\r\n* Symptomatic coronary artery disease (CAD), e.g., angina Canadian class II-IV; in any patient in whom there is doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present\r\n* An ECG recorded at screening showing evidence of cardiac ischemia (ST depression of >=  mm, measured from isoelectric line to the ST segment); if in any doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present\r\n* Other significant ECG abnormalities including nd degree atrio-ventricular (AV) block type II, rd degree AV block, or bradycardia (defined here as ventricular rate <  beats per minute [bpm]); right bundle-branch block + left anterior hemi-block (bifascicular block)\r\n* Congestive heart failure (CHF) that meets New York Heart Association (NYHA) class II to IV definitions and/or ejection fraction < % by multi gated acquisition scan (MUGA) scan or < % by echocardiogram and/or magnetic resonance imaging (MRI) history or presence of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), torsade de pointes, or cardiac arrest\r\n* Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes\r\n* Uncontrolled hypertension, i.e., blood pressure (BP) of >= /; patients who have a history of hypertension controlled by medication must be on a stable dose (for at least one month) and meet all other inclusion criteria\r\n* Any cardiac arrhythmia requiring an anti-arrhythmic medication, excluding stable (i.e., at least  days from screening) doses of beta-blockers
Any known cardiac abnormalities such as:\r\n* Congenital long QT syndrome\r\n* Corrected QT (QTc) interval >=  milliseconds\r\n* Patients taking drugs leading to significant QT prolongation\r\n* Myocardial infarction within  months of cycle day  (CD); (subjects with a history of myocardial infarction between  and  months prior to CD who are asymptomatic and have had a negative cardiac risk assessment [treadmill stress test, nuclear medicine stress test, or stress echocardiogram] since the event, may participate)\r\n* Other significant electrocardiogram (ECG) abnormalities including nd degree atrio-ventricular (AV) block type II, rd degree AV block, or bradycardia (ventricular rate less than  beats/min)\r\n* Symptomatic coronary artery disease (CAD), e.g., angina Canadian class II-IV; in any patient in whom there is doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present\r\n* An ECG recorded at screening showing evidence of cardiac ischemia (ST depression of >=  mm, measured from isoelectric line to the ST segment); if in any doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present\r\n* Congestive heart failure (CHF) that meets New York Heart Association (NYHA) class II to IV definitions and/or ejection fraction < % by multi gated acquisition (MUGA) scan or < % by echocardiogram and/or magnetic resonance imaging (MRI)\r\n* A known history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), Torsade de Pointes, or cardiac arrest \r\n* Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes\r\n* Uncontrolled hypertension, i.e., blood pressure (BP) of >= /; patients who have a history of hypertension controlled by medication must be on a stable dose (for at least one month) and meet all other inclusion criteria or\r\n* Any cardiac arrhythmia requiring an anti-arrhythmic medication (excluding stable doses of beta-blockers)
Symptomatic coronary artery disease (CAD), e.g., angina Canadian class II-IV; in any patient in whom there is doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present
An ECG recorded at screening showing evidence of cardiac ischemia (ST depression of >=  mm, measured from isoelectric line to the ST segment); if in any doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present
Any of the following cardiac abnormalities (only for patients receiving romidepsin):\r\n* Congenital long QT syndrome;\r\n* Corrected QT (QTc) interval ?  milliseconds;\r\n* Patients taking drugs leading to significant QT prolongation;\r\n* Myocardial infarction within  months of cycle , day ; (Subjects with a history of myocardial infarction between  and  months prior to cycle , day , who are asymptomatic and have had a negative cardiac risk assessment [treadmill stress test, nuclear medicine stress test, or stress echocardiogram] since the event, may participate);\r\n* Other significant electrocardiogram (ECG) abnormalities including nd degree atrio-ventricular (AV) block type II, rd degree AV block, or bradycardia (ventricular rate less than  beats/min);\r\n* Symptomatic coronary artery disease (CAD), e.g., angina Canadian class II-IV; in any patient in whom there is doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present;\r\n* An ECG recorded at screening showing evidence of cardiac ischemia (ST depression of ?  mm, measured from isoelectric line to the ST segment); if in any doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present;\r\n* Congestive heart failure (CHF) that meets New York Heart Association (NYHA) class II to IV definitions and/or ejection fraction < % by multitargeted acquisition (MUGA) scan or < % by echocardiogram and/or magnetic resonance imaging (MRI);\r\n* A known history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), torsade de pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD);\r\n* Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes;\r\n* Uncontrolled hypertension, i.e., blood pressure (BP) of ? /; patients who have a history of hypertension controlled by medication must be on a stable dose (for at least one month) and meet all other inclusion criteria; or\r\n* Any cardiac arrhythmia requiring an anti-arrhythmic medication (excluding stable doses of beta-blockers)
Significant cardiac abnormalities such as:\r\n* Myocardial infarction within  months of course  day  (CD); (subjects with a history of myocardial infarction between  and  months prior to CD who are asymptomatic and have had a negative cardiac risk assessment [treadmill stress test, nuclear medicine stress test, or stress echocardiogram] since the event, may participate);\r\n* An electrocardiogram (ECG) recorded at screening showing evidence of cardiac ischemia (ST depression of >=  mm, measured from isoelectric line to the ST segment); if in any doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not coronary artery disease (CAD) is present;\r\n* Congestive heart failure (CHF) that meets New York Heart Association (NYHA) class III to IV definitions and/or ejection fraction < % by multigated acquisition scan (MUGA) scan or < % by echocardiogram and/or magnetic resonance imaging (MRI)
Symptomatic coronary artery disease (CAD), e.g., angina Canadian class II-IV; in any patient in whom there is doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present
An EKG recorded at screening showing evidence of cardiac ischemia (ST depression of >=  mm, measured from isoelectric line to the ST segment); if in any doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present
Any known cardiac abnormalities such as: \r\n* Congenital long QT syndrome \r\n* Corrected QT (QTc) interval >=  milliseconds;\r\n* Myocardial infarction within  months of course  day  (CD); subjects with a history of myocardial infarction between  and  months prior to CD who are asymptomatic and have had a negative cardiac risk assessment (treadmill stress test, nuclear medicine stress test, or stress echocardiogram) since the event may participate;\r\n* Other significant electrocardiogram (ECG) abnormalities including nd degree atrio-ventricular (AV) block type II, rd degree AV block, or bradycardia (ventricular rate less than  beats/min) trial treatments\r\n* Symptomatic coronary artery disease (CAD), e.g., angina; in any patient in whom there is doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present;\r\n* An ECG recorded at screening showing evidence of cardiac ischemia (ST depression, depression of >=  mm, measured from isoelectric line to the ST segment); if in any doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present;\r\n* Congestive heart failure (CHF) that meets New York Heart Association (NYHA) class II to IV definitions and/or ejection fraction < % by multi gated acquisition (MUGA) scan or < % by echocardiogram and/or magnetic resonance imaging (MRI); \r\n* A known history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), torsade de pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD); \r\n* Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes; \r\n* Uncontrolled hypertension, i.e., blood pressure (BP) of >= /; patients who have a history of hypertension controlled by medication must be on a stable dose (for at least one month) and meet all other inclusion criteria; or \r\n* Any cardiac arrhythmia requiring an anti-arrhythmic medication (excluding stable doses of beta-blockers)\r\n* Patients taking drugs leading to significant QT prolongation
The following cardiac abnormalities:\r\n* Congenital long QT syndrome\r\n* Corrected QT (QTc)/ Fridericia's correction QT (QTf) interval >=  milliseconds; unless secondary to pacemaker or bundle branch block\r\n* Myocardial infarction within  months (subjects with a history of myocardial infarction within the last  to  months who are asymptomatic and have had a negative cardiac risk assessment [treadmill stress test, nuclear medicine stress test, or stress echocardiogram] since the event may participate)\r\n* Other significant electrocardiogram (ECG) abnormalities including nd degree atrio-ventricular (AV) block type II, rd degree AV block\r\n* Symptomatic coronary artery disease (CAD), e.g. angina Canadian class II-IV; in any patient in whom there is doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present\r\n* An ECG recorded at screening showing evidence of cardiac ischemia (ST depression of >=  mm, measured from isoelectric line to the ST segment); if in any doubt, the patient should have a stress imaging study and. if abnormal, angiography to define whether or not CAD is present\r\n* Congestive heart failure (CHF) that meets New York Heart Association (NYHA) class II to IV and/or ejection fraction < % by multigated acquisition (MUGA), echocardiogram, or cardiac magnetic resonance imaging (MRI)\r\n* A known history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), torsade de pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD)\r\n* Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes\r\n* Uncontrolled hypertension, i.e., blood pressure (BP) of >= /; patients who have a history of hypertension controlled by medication must be on a stable dose (for at least one month prior to study registration) and meet all other inclusion criteria\r\n* Any cardiac arrhythmia requiring an anti-arrhythmic medication (excluding stable doses of beta-blockers)\r\n* For patients enrolling on the romidepsin arm; taking drugs associated with significant QTc/QTf prolongation, unless able to be switched to non-QTc/QTf prolonging medication or on a stable dose without significant QT prolongation (>  msec)\r\n** Caution should be used when administering study drugs to patients taking medications significantly metabolized by these enzymes; particular attention should be paid to patients receiving warfarin; patients should have coagulation parameters monitored regularly, and warfarin dose adjusted accordingly; if these drugs cannot be discontinued or replaced, enrollment may be allowed after discussion with MSK principle investigator (PI)
Any known cardiac abnormalities such as:\r\n* Congenital long QT syndrome\r\n* Corrected QT (QTc) interval >=  milliseconds\r\n* Myocardial infarction within  months of transplantation; subjects with a history of myocardial infarction between  and  months prior to transplant who are asymptomatic and have had a negative cardiac risk assessment (treadmill stress test, nuclear medicine stress test, or stress echocardiogram) since the event may participate\r\n* Other significant electrocardiogram (ECG) abnormalities including nd degree atrio-ventricular (AV) block type II, rd degree AV block, or bradycardia (ventricular rate less than  beats/min)\r\n* Symptomatic coronary artery disease (CAD), e.g., angina Canadian class II-IV; in any patient in whom there is doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present\r\n* An ECG recorded at screening showing evidence of cardiac ischemia (ST depression of >=  mm, measured from isoelectric line to the ST segment); if in any doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present\r\n* Congestive heart failure (CHF) that meets New York Heart Association (NYHA) class II to IV definitions and/or ejection fraction < % by multi gated acquisition (MUGA) scan or < % by echocardiogram and/or magnetic resonance imaging (MRI)\r\n* A known history or sustained ventricular tachycardia (VT), ventricular fibrillation (VF), torsade de pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD)\r\n* Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes\r\n* Uncontrolled hypertension, defined as blood pressure (BP) >= /; patients who have a history of hypertension controlled by medication must be on a stable dose (for at least one month) and meet all other inclusion criteria\r\n* Any cardiac arrhythmia requiring an anti-arrhythmic medication (excluding stable doses of beta-blockers)\r\n* Patients taking drugs leading to significant QT prolongation within the specified wash out period\r\n* Concomitant use of cytochrome P, family , subfamily A, polypeptide  (CYPA) inhibitors
Subject has active cardiac disease or a history of cardiac dysfunction including any of the following:\r\n* Congenital long QT syndrome\r\n* Corrected QT (QTc) interval >=  ms on the screening electrocardiogram (ECG) (using the corrected QT Fridericia [QTcF] formula)\r\n* Myocardial infarction within  months of course  day  (CD); subjects with a history of myocardial infarction between  and  months prior to CD who are asymptomatic and have had a negative cardiac risk assessment (treadmill stress test, nuclear medicine stress test, or stress echocardiogram) since the event may participate\r\n* Other significant ECG abnormalities including nd degree atrio-ventricular (AV) block type II, rd degree AV block, or bradycardia (ventricular rate less than  beats/min)\r\n* Symptomatic coronary artery disease (CAD), e.g., angina Canadian class II-IV; in any subject in whom there is doubt, the subject should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present\r\n* An ECG recorded at screening showing evidence of cardiac ischemia (ST depression of >=  mm, measured from isoelectric line to the ST segment); if in any doubt, the subject should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present\r\n* Congestive heart failure (CHF) that meets New York Heart Association (NYHA) class II to IV definitions and/or ejection fraction < % by multi gated acquisition (MUGA) scan or < % by echocardiogram and/or magnetic resonance imaging (MRI)\r\n* A known history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), torsade de pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD)\r\n* Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes\r\n* Uncontrolled hypertension, i.e., blood pressure (BP) of >= /; subjects who have a history of hypertension controlled by medication must be on a stable dose (for at least one month) and meet all other inclusion criteria\r\n* Any cardiac arrhythmia requiring an anti-arrhythmic medication (excluding stable doses of beta-blockers)\r\n* Subjects taking drugs leading to significant QT prolongation\r\n* Concomitant use of cytochrome P family , subfamily A, polypeptide  (CYPA) inhibitors
Symptomatic coronary artery disease (CAD), e.g., angina Canadian class II-IV; in any patient in whom there is doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present
An ECG recorded at screening showing evidence of cardiac ischemia (ST depression of >=  mm, measured from isoelectric line to the ST segment); if in any doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present
Any known cardiac abnormalities such as:\r\n* Congenital long QT syndrome\r\n* Corrected QT (QTc) interval >=  milliseconds\r\n* Patients taking drugs leading to significant QT prolongation \r\n* Myocardial infarction within  months of course  day  (CD); (subjects with a history of myocardial infarction between  and  months prior to CD who are asymptomatic and have had a negative cardiac risk assessment [treadmill stress test, nuclear medicine stress test, or stress echocardiogram] since the event, may participate)\r\n* Other significant electrocardiogram (ECG) abnormalities including nd degree atrio-ventricular (AV) block type II, rd degree AV block, or bradycardia (ventricular rate less than  beats/min)\r\n* Symptomatic coronary artery disease (CAD), e.g., angina Canadian class II-IV; in any patient in whom there is doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present\r\n* An ECG recorded at screening showing evidence of cardiac ischemia (ST depression of >=  mm, measured from isoelectric line to the ST segment); if in any doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present\r\n* Congestive heart failure (CHF) that meets New York Heart Association (NYHA) class II to IV definitions and/or ejection fraction < % by multigated acquisition (MUGA) scan or < % by echocardiogram and/or MRI;\r\n* A known history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), Torsade de Pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD)\r\n* Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes\r\n* Uncontrolled hypertension, i.e., blood pressure (BP) of >= /; patients who have a history of hypertension controlled by medication must be on a stable dose (for at least one month) and meet all other inclusion criteria; or\r\n* Any cardiac arrhythmia requiring an anti-arrhythmic medication (excluding stable doses of beta-blockers)
The following cardiac abnormalities:\r\n* Congenital long QT syndrome\r\n* Corrected QT (QTc) interval >=  milliseconds\r\n** A QTc interval between - milliseconds (msec) in the presence of a bundle branch block (BBB) or pacemaker is eligible in phase IIa after discussion with MSK principal investigator\r\n* Myocardial infarction within  months of cycle one, day one (CD); subjects with a history of myocardial infarction between  and  months prior to CD who are asymptomatic and have had a negative cardiac risk assessment (treadmill stress test, nuclear medicine stress test, or stress echocardiogram) since the event may participate\r\n* Other significant electrocardiogram (ECG) abnormalities including second (nd) degree atrio-ventricular (AV) block type II, third (rd) degree AV block\r\n* Symptomatic coronary artery disease (CAD), e.g., angina Canadian class II-IV; in any patient in whom there is doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present\r\n* An ECG recorded at screening showing evidence of cardiac ischemia (ST depression of >=  mm, measured from isoelectric line to the ST segment); if in any doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present\r\n* Congestive heart failure (CHF) that meets New York Heart Association (NYHA) class II to IV definitions and/or ejection fraction < % by multi gated acquisition scan (MUGA), ECG, or cardiac magnetic resonance imaging (MRI)\r\n* A known history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), torsades de pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD)\r\n* Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes\r\n* Uncontrolled hypertension, i.e., blood pressure (BP) of >= /; patients who have a history of hypertension controlled by medication must be on a stable dose (for at least one month) and meet all other inclusion criteria\r\n* Any cardiac arrhythmia requiring an anti-arrhythmic medication (excluding stable doses of beta-blockers)
Any known cardiac abnormalities such as:\r\n* Congenital long QT syndrome\r\n* Corrected QT (QTc) interval >=  milliseconds;\r\n* Myocardial infarction within  months of cycle , day  (CD); subjects with a history of myocardial infarction between  and  months prior to CD who are asymptomatic and have had a negative cardiac risk assessment (treadmill stress test, nuclear medicine stress test, or stress echocardiogram) since the event may participate;\r\n* Other significant electrocardiogram (ECG) abnormalities including second (nd) degree atrio-ventricular (AV) block type II, third (rd) degree AV block, or bradycardia (ventricular rate less than  beats/min);\r\n* Symptomatic coronary artery disease (CAD), e.g., angina; in any patient in whom there is doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present;\r\n* An ECG recorded at screening showing evidence of cardiac ischemia (ST depression, depression of >=  mm, measured from isoelectric line to the ST segment); if in any doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present;\r\n* Congestive heart failure (CHF) that meets New York Heart Association (NYHA) class II to IV definitions and/or ejection fraction < % by multi gated acquisition scan (MUGA) scan or < % by echocardiogram and/or magnetic resonance imaging (MRI);\r\n* A known history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), torsade de pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD);\r\n* Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes;\r\n* Uncontrolled hypertension, i.e., blood pressure (BP) of >= /; patients who have a history of hypertension controlled by medication must be on a stable dose (for at least one month) and meet all other inclusion criteria; or\r\n* Any cardiac arrhythmia requiring an anti-arrhythmic medication (excluding stable doses of beta-blockers)
Symptomatic coronary artery disease (CAD), e.g., angina Canadian class II-IV; in any patient in whom there is doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present
An EKG recorded at screening showing evidence of cardiac ischemia (ST depression of >=  mm, measured from isoelectric line to the ST segment); if in any doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present
Any known cardiac abnormalities such as:\r\n* Congenital long QT syndrome\r\n* QTc interval >=  milliseconds;\r\n* Myocardial infarction within  months of course , day  (CD); subjects with a history of myocardial infarction between  and  months prior to CD who are asymptomatic and have had a negative cardiac risk assessment (treadmill stress test, nuclear medicine stress test, or stress echocardiogram) since the event may participate;\r\n* Other significant electrocardiogram (ECG) abnormalities including nd degree atrio-ventricular (AV) block type II, rd degree AV block, or bradycardia (ventricular rate less than  beats/min);\r\n* Symptomatic coronary artery disease (CAD), e.g., angina Canadian class II-IV; in any patient in whom there is doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present;\r\n* An ECG recorded at screening showing evidence of cardiac ischemia (ST depression of >=  mm, measured from isoelectric line to the ST segment); if in any doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present;\r\n* Congestive heart failure (CHF) that meets New York Heart Association (NYHA) class II to IV definitions and/or ejection fraction < % by multi gated acquisition (MUGA) scan or < % by echocardiogram and/or magnetic resonance imaging (MRI);\r\n* A known history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), Torsade de Pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD);\r\n* Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other cause;\r\n* Any cardiac arrhythmia requiring an anti-arrhythmic medication (excluding stable doses of beta-blockers)
